News
Despite boasting a new owner, the Indiana manufacturing plant that Novo Nordisk picked up as part of its parent company's ...
With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...
On Friday, Novo Nordisk announced that the U.S. Food and Drug Administration (FDA) had approved Wegovy for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). Wegovy has become a ...
No one stays on top forever. It’s a lesson that Ozempic maker Novo Nordisk may be painfully learning about. The Danish ...
A Comeback Fueled by Resilience Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) has been a trailblazer in the GLP-1 drug ...
Novo Nordisk is slashing the price of its blockbuster diabetes drug Ozempic for U.S. patients who self-pay or are uninsured.
Novo Nordisk said on Friday the U.S. Food and Drug Administration has granted accelerated approval for its weight-loss drug ...
The pharma giant has almost doubled the size of its workforce over the last five years but is now looking to tighten cost ...
1d
TipRanks on MSNNovo Nordisk’s New Weight Control Drug: A Promising Update for Investors
Novo Nordisk (($DE:NOVA)) announced an update on their ongoing clinical study. Study Overview: Novo Nordisk has completed a clinical study titled ...
1d
TipRanks on MSNNovo Nordisk’s Latest Study on Obesity Drug NNC0487-0111: Key Insights for Investors
Novo Nordisk (($DE:NOVA)) announced an update on their ongoing clinical study. Study Overview: Novo Nordisk has completed a study titled A ...
Novo Nordisk shares climbed after the U.S. Food and Drug Administration approved a new indication for the Danish drugmaker’s ...
Novo Nordisk's economic moat is eroding due to increased competition and US drug price pressures, but growth in international ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results